Bionomics Ltd. - BNOX Market Value

The financial model of Bionomics Limited (BNOX) relies on the results of final trials for key CNS drugs. The company develops innovative small molecules targeting GABA receptors for the treatment of psychiatric disorders. This chart reflects a current market valuation of 0.00, while the business does not yet generate revenue, and its sustainability depends directly on future success in clinical trials.

BNOX (Bionomics Ltd.) Market Capitalization history from 07/04/2022 to 12/24/2024

Comprehensive metric breakdowns and analytics for bionomics.com.au (BNOX)

- market price and analyst price targets:

Price Chart Bionomics|BNOX - Broker Consensus Forecast

- issuer market value details:

Market Value Bionomics Limited|BNOX - Total Enterprise Value

- book value of equity indicators:

Accounting Value per Share Bionomics|BNOX - Accounting Capitalization|Market Value to Book Value Ratio bionomics.com.au|BNOX - Total Asset Value of Company

- debt and liquidity data:

- net income and valuation multiples indicators:

BNOX - Net Profit|Future Profit Bionomics Limited|BNOX - Company Value to Net Income|Future Price to Earnings Bionomics|BNOX - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Bionomics Limited|BNOX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Bionomics|BNOX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months bionomics.com.au|BNOX - Earnings per share increase in current year|Net earnings per share growth forecast for next year Bionomics Limited

Fundamental company analysis:BNOX (Bionomics Ltd)

Bionomics Limited focuses on developing neurological drugs and protecting intellectual property across key regions. Analyzing the company's market valuation history, an investor sees the aggregate value of all outstanding shares. This metric is calculated by multiplying the current share price by the total number of issued securities. This indicator reflects the market value of the business, incorporating expectations regarding the clinical efficacy of the drugs. The current level on the chart expresses the market's collective opinion on the potential for future partnerships.

Key competitors